limited to 50 SBP: (SEM: 4.01, CI: 70mmol/day mmol/24hr 5.16) All participants Low sodium DBP: -2.5mmHg (SEM: 2.46, received in random period: 72 + CI: -7.32, 2.32) order 31 From the article: mean chlorthalidone, mmol/24hr difference in BP during metoprolol, a fixed (p<0.05) placebo period: combination of these drugs for 4 SBP: -2.7 +2.2 (p=0.12) weeks each, (supine), -4.4 + 2.3 alternated with 4 (p=0.025) (standing) weeks of placebo DBP: -3.4 +1.7 (p=0.025) (supine), -1.0 + 1.6 (p=0.25) (standing) States there was no significant change in cholesterol and HDL, but does not give specific results for normal and low sodium diets Key features for bias assessment of randomised trials Citation Method of Allocation Blinding Loss to Use of Ceasing Reporting all Funding randomisation concealment follow-up study early outcome results source for benefit
limited to 70mmol/day All participants received in random order chlorthalidone, metoprolol, a fixed combination of these drugs for 4 weeks each, alternated with 4 weeks of placebo 50 mmol/24hr Low sodium period: 72 + 31 mmol/24hr (p<0.05) SBP: (SEM: 4.01, CI: 5.16) DBP: -2.5mmHg (SEM: 2.46, CI: -7.32, 2.32) From the article: mean difference in BP during placebo period: SBP: -2.7 +2.2 (p=0.12) (supine), -4.4 + 2.3 (p=0.025) (standing) DBP: -3.4 +1.7 (p=0.025) (supine), -1.0 + 1.6 (p=0.25) (standing) States there was no significant change in cholesterol and HDL, but does not give specific results for normal and low sodium diets Key features for bias assessment of randomised trials Citation Method of randomisation Allocation concealment Blinding Loss to follow-up Use of Ceasing study early for benefit Reporting all outcome results Funding source
Sodium%20Supporting%20Document%201%20%20Systematic%20Literature%20Review.docx